/URGN
URGN Stock - UroGen Pharma Ltd.
Healthcare|BiotechnologyNASDAQ
$22.80+4.97%
+$1.08 (+4.97%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.86
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).56
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+3.1%upside
Target: $23.51
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for URGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$22.57 – $23.03
TARGET (TP)$23.50
STOP LOSS$20.98
RISK/REWARD1:0.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$30.00
52W Low$3.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $90.40M | $82.71M | $64.36M | $48.04M | $11.80M |
| Gross Profit | $81.52M | $73.35M | $56.70M | $42.88M | $10.79M |
| Gross Margin | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% |
| Operating Income | $-96,782,000 | $-65,536,000 | $-79,041,000 | $-92,292,000 | $-126,739,000 |
| Net Income | $-126,874,000 | $-102,244,000 | $-109,783,000 | $-110,820,000 | $-128,484,000 |
| Net Margin | -140.4% | -123.6% | -170.6% | -230.7% | -1088.9% |
| EPS | $-2.96 | $-3.55 | $-4.79 | $-4.96 | $-5.90 |
Company Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
71%
Hold / Neutral
2
29%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish2 Neutral/Bearish
Price Targets
$30
Average Target
↑ 31.6% Upside
Now
$10
Low
$30
Average
$50
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $36 |
| June 16th 2025 | H.C. Wainwright | Upgrade | Buy | $50 |
| May 22nd 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| April 16th 2025 | Scotiabank | Initiation | Sector Outperform | $23 |
| February 19th 2025 | Ladenburg Thalmann | Resumed | Buy | $31 |
| August 22nd 2024 | Guggenheim | Initiation | Buy | $40 |
| February 8th 2023 | Jefferies | Downgrade | Hold | $10← $35 |
| April 27th 2022 | Berenberg | Initiation | Buy | $20 |
Earnings History & Surprises
URGNBeat Rate
44%
Last 18 quarters
Avg Surprise
-0.2%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.69
Q4 2025
EPS Surprise History
Q1 24
-7.5%
$-0.72vs$-0.67
Q2 24
-4.3%
$-0.97vs$-0.93
Q3 24
-11.0%
$-0.91vs$-0.82
Q4 24
+34.5%
$-0.55vs$-0.84
Q1 25
-15.9%
$-0.80vs$-0.69
Q2 25
-10.8%
$-0.92vs$-0.83
Q3 25
-28.0%
$-1.05vs$-0.82
Q4 25
+4.2%
$-0.69vs$-0.72
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.65 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.72 | $-0.69 | +4.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.82 | $-1.05 | -28.0% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.83 | $-0.92 | -10.8% | ✗ MISS |
Q1 2025 | Mar 10, 2025 | $-0.69 | $-0.80 | -15.9% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.84 | $-0.55 | +34.5% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.82 | $-0.91 | -11.0% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.93 | $-0.97 | -4.3% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.67 | $-0.72 | -7.5% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.89 | $-0.68 | +23.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.13 | $-1.03 | +8.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.39 | $-1.30 | +6.5% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-1.12 | $-1.22 | -8.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1.22 | $-1.13 | +7.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.33 | $-1.18 | +11.3% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-1.36 | $-1.25 | +8.1% | ✓ BEAT |
Q1 2022 | Mar 21, 2022 | $-1.18 | $-1.27 | -7.6% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-1.26 | $-1.35 | -7.1% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-1.10 | $-1.17 | -6.4% | ✗ MISS |
Latest News
UroGen Pharma Q3 EPS $(0.69), Inline, Sales $27.500M Miss $33.093M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 01:02 PM
UroGen Pharma Data From Phase 3 UTOPIA Study Shows A 77.8% Three-Month Complete Response Rate With UGN-103 For Intravesical Solution In Patients With Recurrent Non-Muscle Invasive Bladder Cancer
📈 PositiveBenzinga•Nov 6, 2025, 01:00 PM
UroGen Pharma shares are trading higher after the Centers for Medicare and Medicaid Services assigned a permanent J code for ZUSDURI, effective January 1.
📈 PositiveBenzinga•Oct 27, 2025, 07:04 PM
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 03:22 PM
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 12:39 PM
UroGen Pharma Announces Centers for Medicare and Medicaid Services Assigned Permanent J Code For ZUSDURI, Effective Jan. 1
📈 PositiveBenzinga•Oct 27, 2025, 12:06 PM
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
📈 PositiveBenzinga•Oct 3, 2025, 12:34 PM
UroGen Publishes Comprehensive Review Of ZUSDURI For Recurrent LG-IR Non–Muscle-Invasive Bladder Cancer, Titled: "Review of UGN-102: A Reverse Thermal Gel Containing Mitomycin for the Treatment of Recurrent, Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer"
📈 PositiveBenzinga•Oct 2, 2025, 12:05 PM
Piper Sandler Initiates Coverage On UroGen Pharma with Overweight Rating, Announces Price Target of $36
📈 PositiveBenzinga•Aug 19, 2025, 12:04 PM
UroGen continues to climb after bladder cancer drug approval
📈 PositiveSeeking Alpha•Jun 13, 2025, 02:24 PM
UroGen closes up 43% ahead of FDA decision on bladder cancer candidate
📈 PositiveSeeking Alpha•Jun 6, 2025, 10:26 PM
UroGen crashes as FDA AdCom rebukes bladder cancer drug
📉 NegativeSeeking Alpha•May 21, 2025, 05:41 PM
UroGen drops 20% as FDA releases docs in advance of AdCom meeting
📉 NegativeSeeking Alpha•May 16, 2025, 04:07 PM
Frequently Asked Questions about URGN
What is URGN's current stock price?
UroGen Pharma Ltd. (URGN) is currently trading at $22.80 per share. The stock has moved +4.97% today.
What is the analyst price target for URGN?
The average analyst price target for URGN is $23.50, based on 1 analyst.
What sector is UroGen Pharma Ltd. in?
UroGen Pharma Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is URGN's market cap?
UroGen Pharma Ltd. has a market capitalization of $1.07 billion, making it a small-cap company.
Does URGN pay dividends?
No, UroGen Pharma Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to URGN for comparison